Type 2 Diabetes
Conditions
Keywords
observational, HbA1c, type 2 diabetes, gliclazide MR, SGLT2i, gliclazide MR combined to SGLT2i, retrospective, chart review
Brief summary
The study objectives are to assess over the gliclazide MR-SGLT2i combined treatment course in patients with T2DM adding SGLT2i to gliclazide MR-based therapy. The primary objective is to determine the effectiveness of adding SGLT2i to gliclazide MR-based therapy in patients with T2DM, as measured by HbA1c changes.
Interventions
None listed
Sponsors
Servier Affaires Médicales
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient diagnosed with T2DM for at least two years prior to index date * Patient aged ≥18 years at the index date * Patient naïve to SGLT2i prior to index date * Patient treated with gliclazide MR at a minimum daily dose of 60 mg at the index date * Starting treatment with SGLT2i added to gliclazide MR based therapy, during the eligibility period, with a minimum of 60 days of combined gliclazide MR-SGLT2i treatment * Presence of at least two assessments of HbA1c laboratory test results from the medical records
Exclusion criteria
* Diagnosis of diabetes other than T2DM (e.g., type 1, gestational) at index date * Use of antidiabetic drugs other than those permitted by the inclusion criteria, at index date
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| effectiveness of adding SGLT2i to gliclazide MR | from index date (date of SGLT2i adding to gliclazide MR) to discontinuation of the combination (at least 2 months) or date of data collection initiation during the eligibility period, loss to follow-up, or death, whichever occurs first (approx 2 months) | To determine the effectiveness of adding SGLT2i to gliclazide MR-based therapy in patients with T2DM, as measured by HbA1c changes (in %) |
Countries
France
Outcome results
None listed